SynBioBeta Speaker
Cindy Groff-Vindman
CINBIO
Founder
Dr. Cindy Groff-Vindman is a molecular geneticist and biotechnology executive focused on the transition of industrial biology from promising science to durable manufacturing businesses within the emerging bioeconomy. Her work sits at the intersection of synthetic biology, industrial biomanufacturing, and national security. Her recent publications explore how advances in AI-enabled bioengineering, industrial biotechnology, and secure biological data systems are reshaping the bioeconomy. She is particularly interested in the emergence of a new generation of industrial bio companies that combine scientific innovation with manufacturing discipline, capital efficiency, and customer-driven product development, as well as encouraging public investment in the infrastructure needed to enable safe, secure, and predictable bioengineering.She is the founder of CINBIO LLC, where she advises venture investors, corporations, and public–private partnerships on disciplined investment, technology readiness, and the operational realities of scaling biotechnology to deliver commercially viable materials and products. Dr. Groff-Vindman previously served as Government Chief Technology Officer for BioMADE, the Manufacturing Innovation Institute established to strengthen the U.S. bioindustrial economy. In that role she helped shape national technology investment strategy and advised on a portfolio of more than $300 million supporting dual-use biomanufacturing platforms, guiding programs from early research through industrial adoption.In government she worked end to end along the technology and acquisition lifecycle from basic research and technology maturation through procurement and fielded capability. She helped develop the U.S. Army’s synthetic biology strategy as an Associate Program Manager for emerging research programs and previously served as Lead Scientist for PM Soldier Clothing and Individual Equipment under PEO Soldier, delivering mission critical technologies. Her career spans biotechnology research and development, federal technology investment strategy, intellectual property, and international science diplomacy. She also served as an officer in the U.S. Army, bringing a perspective that integrates technical innovation, operational discipline, and national security considerations in emerging biological technologies.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Cindy
This Year
•
-
Biomanufacturing
The Road to Commercial Scale: Capital and Market Demands Beyond the Pilot Plant
Scaling bio-based products to commercial production requires balancing technical readiness with market and financial realities. This session examines the capital investments, regulatory planning, and supply chain strategies necessary to move beyond the pilot stage. Experts will share lessons on aligning production capacity with demand forecasts, managing operational risk, and structuring partnerships that unlock funding and market access. Attendees will gain practical insights into navigating investor expectations, scaling efficiently without compromising quality, and making strategic decisions that ensure products can succeed commercially while meeting evolving market needs and sustainability goals.
Featuring
Per Falholt
21st.BIO
CSO, Co-founder
Launched ~200 enzyme products, industrial biotech scale-up expert
Vanderlei Bellettini
ADM
VP Precision Ferm. Ops
Bioprocess scale-up veteran turning fermentation into real-world products
Richard Kenny
Hawkwood Bio
Founder & Mng. Partner
Techno-economic analysis for the bioeconomy
Verena Kallhoff
GHP
Sr. Dir, Global Life Sciences
Riccardo LoCascio
Novonesis
Partnering - Precision Proteins
Cindy Groff-Vindman
CINBIO
Founder
•
-
Biomanufacturing
The Road to Commercial Scale: Capital and Market Demands Beyond the Pilot Plant
Scaling bio-based products to commercial production requires balancing technical readiness with market and financial realities. This session examines the capital investments, regulatory planning, and supply chain strategies necessary to move beyond the pilot stage. Experts will share lessons on aligning production capacity with demand forecasts, managing operational risk, and structuring partnerships that unlock funding and market access. Attendees will gain practical insights into navigating investor expectations, scaling efficiently without compromising quality, and making strategic decisions that ensure products can succeed commercially while meeting evolving market needs and sustainability goals.
Featuring
Per Falholt
21st.BIO
CSO, Co-founder
Launched ~200 enzyme products, industrial biotech scale-up expert
Vanderlei Bellettini
ADM
VP Precision Ferm. Ops
Bioprocess scale-up veteran turning fermentation into real-world products
Richard Kenny
Hawkwood Bio
Founder & Mng. Partner
Techno-economic analysis for the bioeconomy
Verena Kallhoff
GHP
Sr. Dir, Global Life Sciences
Riccardo LoCascio
Novonesis
Partnering - Precision Proteins
Cindy Groff-Vindman
CINBIO
Founder
Session lineup still growing
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Featuring
Speaker Coming Soon
